$BMRA

Irani Zackary S. purchased $50K of BMRA

Irani Zackary S. (Chief Executive Officer) purchased 31,250 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-26.

Original reporting
SEC EDGAR · Irani Zackary S.
Published Aug 27, 2026, 9:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 10:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BMRA
Neutral
medium confidence
Mentioned
$BMRA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BMRANeutralLow
01

Why it matters

The transaction adds 31,250 shares to the CEO's holdings, raising his stake to 242,570 shares.

02

Market read

A modest insider buy; limited immediate market impact but worth monitoring for future insider activity.

03

What to watch

Potential upcoming clinical data releases could make the insider activity more meaningful.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑08‑26

Background

Form 4 filings disclose insider trades; investors watch CEO purchases for confidence signals.

Company-level read

Ticker impact

$BMRANeutralMedium confidence
Context

CEO Irani Zackary S. bought 31,250 shares for $50,000 in an open‑market purchase reported on Form 4.

Expected impact

Limited short‑term impact; may provide slight upside bias if accumulation continues.

Evidence & confidence

The filing is the first public disclosure of the transaction, but the $50k size is small for a public company, reducing materiality.

Market effects

None significant; biotech sector unchanged.

No regional effect.

Minimal.

Counterpoint

The purchase could be a routine portfolio rebalancing rather than a strong bullish signal.

Key entities

  • Irani Zackary S.

    Chief Executive Officer of Biomerca Inc.

  • Biomerca Inc.

    Biotech company listed under ticker BMRA.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BMRAMedAI 9/10

Biomerica Wins $1.75M Contract to Develop Diagnostic Tests

Biomerica Inc. said it was selected for a $1.75 million master services agreement with an undisclosed life sciences company to develop in vitro diagnostic assays. The three-year work will be performed at Biomerica’s Irvine facility, according to the company. Biomerica said the initial fees provide near-term revenue visibility. Shares fell 2.2% to $2.40.